Advertisement

Current Atherosclerosis Reports

, Volume 14, Issue 2, pp 130–134 | Cite as

The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease

  • Jamal S. RanaEmail author
  • S. Matthijs Boekholdt
  • John J. P. Kastelein
  • Prediman K. Shah
Coronary Heart Disease (J Farmer, Section Editor)

Abstract

Despite aggressive lipid-lowering therapy, patients continue to be at significant risk of coronary heart disease (CHD). Assessment of non–high-density lipoprotein cholesterol (non–HDL-C) provides a measure of cholesterol contained in all atherogenic particles. In the third Adult Treatment Panel (ATP III) guidelines of the US National Cholesterol Education Program, non–HDL-C was introduced as a secondary target of therapy in persons with triglycerides ≥200 mg/dL. A recent meta-analysis of the relationship between non–HDL-C reduction and CHD risk showed non–HDL-C as an important target of therapy for CHD prevention. Most lipid-modifying drugs used as monotherapy have a 1:1 relationship between percent non–HDL-C lowering and percent CHD reduction. In the EPIC-Norfolk prospective population study, 21,448 participants without diabetes or CHD between 45 and 79 years of age were followed for 11.0 years. Participants with high non–HDL-C levels were at increased CHD risk independently of their LDL-C levels. Also, compared to apolipoprotein B, non–HDL-C appears to be a better choice given the fact that no additional tests or costs are needed and established cut points are already available. Future guidelines should emphasize the importance of non–HDL-C for guiding cardiovascular prevention strategies with an increased need to have non–HDL-C reported on routine lipid panels.

Keywords

Low-density lipoprotein cholesterol Non-HDL cholesterol Apolipoprotein B Coronary heart disease 

Notes

Disclosure

J.S. Rana: none; S.M. Boekholdt: none; J.J.P. Kastelein serves as a consultant for a number of pharmaceutical companies who have molecules in development for the treatment of dyslipidemia: Merck, Roche, Novartis, Isis, Genzyme, Aegerion, Cerenis, AstraZeneca, Sanofi-Aventis; P.K. Shah: none.

References

Papers of particular interest, published recently, have been highlighted as • Of importance •• Of major importance

  1. 1.
    Kannel WB, Dawber TR, Thomas Jr HE, McNamara PM. Comparison of serum lipids in the prediction of coronary heart disease. Framingham Study indicates that cholesterol level and blood pressure are major factors in coronary heart disease; effect of obesity and cigarette smoking also noted. R I Med J. 1965;48:243–50.PubMedGoogle Scholar
  2. 2.
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.Google Scholar
  3. 3.
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.CrossRefGoogle Scholar
  4. 4.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRefGoogle Scholar
  5. 5.
    Sacks FM, Pfeffer MA, Moye LA, on behalf of the Cholesterol and Recurrent Events Trial Investigators, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRefGoogle Scholar
  7. 7.
    Grundy SM, Cleeman JI, Daniels SR, on behalf of the American Heart Association and National Heart, Lung, and Blood Institute, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.PubMedCrossRefGoogle Scholar
  8. 8.
    • Robinson JG. Are you targeting non-high-density lipoprotein cholesterol? J Am Coll Cardiol. 2009;55(1):42–4. This is an editorial outlining the importance of measuring and targeting non-HDL cholesterol. PubMedCrossRefGoogle Scholar
  9. 9.
    Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The residual risk reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(10 Suppl):1K–34K.PubMedCrossRefGoogle Scholar
  10. 10.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction-22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.PubMedCrossRefGoogle Scholar
  12. 12.
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, for the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.PubMedCrossRefGoogle Scholar
  13. 13.
    Kearney PM, Blackwell PM, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C, for the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a metaanalysis. Lancet. 2008;371:117–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Milani RV, Lavie CJ. Another step forward in refining risk stratification: moving past low-density lipoprotein cholesterol. J Am Coll Cardiol. 2011;58:464–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non–high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Cui Y, Blumenthal RS, Flaws JA, et al. Non–high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298:776–85.PubMedCrossRefGoogle Scholar
  18. 18.
    Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98:1363–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28:1916–21.PubMedCrossRefGoogle Scholar
  20. 20.
    • Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931–9. In this prospective study of healthy women, cardiovascular disease risk prediction associated with lipoprotein profiles evaluated by NMR was comparable but not superior to that of standard lipids or apolipoproteins. PubMedCrossRefGoogle Scholar
  21. 21.
    •• Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ,Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000. An analysis of more than 300 000 people demonstrated that lipid assessment in vascular disease can be simplified by measurement of either cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride. Hazard ratios with non–HDL-C and HDL-C were nearly identical to those seen with apoB and apoA-I. PubMedCrossRefGoogle Scholar
  22. 22.
    •• Arsenault BJ, Rana JS, Stroes ESG, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non– high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2010;55:35–41. This analyses showed that that irrespective of LDL-C levels, participants with elevated non–HDL-C levels have a substantially higher risk of developing CHD. Also, non–HDL-C levels not only account for the risk associated with LDL-C, but also provide more information about CHD risk associated with elevated lipid levels than LDL-C levels alone. CrossRefGoogle Scholar
  23. 23.
    •• Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337–45. This meta-analysis including 23,455 subjects and 22,950 events evaluated relative risk ratio for cardiovascular risk between LDL, non-HDL-C, and apoB. PubMedCrossRefGoogle Scholar
  24. 24.
    Lavie CJ, Milani RV, O’Keefe JH. To B or not to B: is noñHigh-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B? Mayo Clin Proc. 2010;85:446–50.PubMedCrossRefGoogle Scholar
  25. 25.
    Holme I, Aastveit AH, Jungner I, Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2008;264:30–8.PubMedCrossRefGoogle Scholar
  26. 26.
    McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.PubMedCrossRefGoogle Scholar
  28. 28.
    •• Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol. 2011;58:457–63. This is a comprehensive commentary on comparison between non-HDL-C and apoB, concluding that non–HDL-C is a better marker of choice for cardiovascular risk stratification at the present time. PubMedCrossRefGoogle Scholar
  29. 29.
    Kastelein JJP, van der Steeg W, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002–9.PubMedCrossRefGoogle Scholar
  30. 30.
    •• Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non– high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316–22. This important meta-analysis showed that non–HDL-C is an important target of therapy for CHD prevention. Most lipid-modifying drugs used as monotherapy have an approximately 1:1 relationship between percent non–HDL-C lowering and CHD reduction. PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jamal S. Rana
    • 1
    • 3
    Email author
  • S. Matthijs Boekholdt
    • 2
  • John J. P. Kastelein
    • 2
  • Prediman K. Shah
    • 1
  1. 1.Division of Cardiology and Oppenheimer Atherosclerosis Research CenterCedars-Sinai Heart Institute, Cedars-Sinai Medical CenterLos AngelesUSA
  2. 2.Department of Vascular Medicine, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  3. 3.Department of CardiologyCedars-Sinai Heart Institute, Cedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations